Marker Therapeutics (MRKR) Equity Average (2011 - 2026)

Marker Therapeutics (MRKR) has 16 years of Equity Average data on file, last reported at $15.3 million in Q1 2026.

• Equity Average for Q1 2026 came in at $15.3 million, down 7.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.3 million (down 7.44% YoY), and the FY2025 annual result was $17.7 million, up 8.42% from the prior year.
• Equity Average slipped to $15.3 million in Q1 2026 per MRKR's latest filing, from $17.6 million in the prior quarter.
• Over five years, Equity Average peaked at $39.8 million in Q1 2022 and troughed at $8.6 million in Q3 2024.
• A 5-year average of $18.1 million and a median of $16.5 million in 2025 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2025: Equity Average sank 56.18% in 2022, then jumped 68.37% in 2025.
• A 5-year view of Equity Average shows it stood at $21.1 million in 2022, then decreased by 27.11% to $15.4 million in 2023, then fell by 15.45% to $13.0 million in 2024, then soared by 35.29% to $17.6 million in 2025, then slipped by 13.05% to $15.3 million in 2026.
• Business Quant data shows MRKR's Equity Average at $15.3 million in Q1 2026, $17.6 million in Q4 2025, and $14.4 million in Q3 2025.